Table 1.

Cytogenetic and Molecular features of AML samples treated with DNMTis in combination with PARPis

PT#	Samplea	Sexb	BM Blastsc	PB Blastsc	Cytogenetic Findingsd	Categorye	Response to DAC/AZA +ABT/BMNf
9	BM	F	-	-	49,XX,11,+21,+3mar[11]/49,XX,i(11)(q10),+3mar[3}	Complex	NO
15	BM	M	-	-	ND	FLT3/ITD	YES
16	BM	F	35	21	46,XX	Unknown	NO
29	PB	F	-	95	46,XX	FLT3/ITD	YES
30	BM	F	-	5	46,XX	Neither	NO
34	PB	-	-	-	ND	FLT3/ITD	YES
081	BM	M	58	0	45–48,XY,-4,+11,+14,-17,-18,+2–4mar	Complex	YES
086	BM	M	86	63	46XY	FLT3/ITD	YES
090	PB	M	-	79	46XY,+8	Neither	NO
092	BM/PB	M	78	94	46–51,XY,+4,+8,+ 3mar	Complex	YES
107	BM	F	92	89	46,XX	FLT3/ITD	NO
109	BM	F	25	5	41–44,XX,-3,del(3)(p21),-5,del(7)(q22q36),-12,-15,- 17,-20,+1–3mar	Complex	YES
110	BM	F	88	91	47,XX,+11	FLT3/ITD	YES

^aBM= Bone Marrow; PB= Peripheral Blood

^bF= female; M= male; hyphen = information unavailable

^cNumbers represent percentages

^dND= Not determined

^eComplex refers to complex karyotype

^fResponse to combination (yes/no) is relative to single drug treatment